Cabaser (cabergoline)-Important Safety Information from Pfizer as approved by the Irish Medicines Board

Notice type: 3rd Party Publications

Date: 28/07/2008

Problem Or Issue:
Please find herewith an important safety communication from Pfizer. Treatment with Cabergoline (Cabaser) has been associated with the onset of fibrotic cardiac valvulopathy.

« Back